# AG1 and Ritual fund clinical trials to convert skeptics into $1.5M+ buyers

*Third-party research transforms supplement claims from marketing copy into defensible science that closes hesitant customers.*

By **Jenny Huang Goodman MPA MSc MHSA, Principal** — The Stash Edge, Hako Shikin LLC.
Published 2026-09-08.

Canonical: https://www.pops4.com/stash/articles/ag1-ritual-blueland-2026-09-08t03-3
Subject: AG1, Ritual, Blueland
Tags: clinical research, third-party validation, supplements, efficacy claims, conversion optimization, brand credibility

---

AG1, Ritual, and Blueland are writing checks for clinical trials and publishing the results, according to Modern Retail. The mechanism is simple: fund a third-party study, publish the data, and use it to answer the buyer who won't convert on a claim alone. AG1 reportedly invested over **$1.5 million** in clinical research to validate product efficacy, turning peer-reviewed findings into the anchor of its growth strategy.

The brands commission university researchers or independent labs to run controlled trials on their formulations. Ritual, for instance, has funded multiple studies examining nutrient absorption and health outcomes tied to its prenatal and multivitamin lines. Blueland, a cleaning-product brand, pursued clinical testing to substantiate environmental and performance claims against conventional cleaners. The studies are published in peer-reviewed journals or made available as white papers, then cited in advertising, on-pack copy, and customer-service scripts.

This works because it converts doubt into proof at the exact moment a prospect needs it. A supplement buyer scrolling Instagram sees ten brands promising energy or gut health; most scroll past. But when a brand can link to a published trial showing statistically significant improvements in a measured outcome, the conversation shifts from belief to evidence. The research becomes a wedge that separates a product from the commodity shelf. It also arms customer service and sales teams with a response to the most expensive objection: "How do I know this actually works?"

The play is accessible to smaller physical-product brands if the scope is right-sized. A candle brand claiming better air quality can commission a **$3,000 to $8,000** lab test measuring particulate emissions compared to paraffin competitors, then publish the report on the site. A skincare line can fund a **$10,000 to $25,000** dermatologist-supervised user trial tracking hydration or irritation over thirty days, recruiting participants through email and offering free product in exchange for data release consent. A food brand can hire a registered dietitian and a small cohort to document satiety or energy metrics, filming the process for content.

The structure: identify the single claim that would most accelerate conversion if proven, then find the lowest-cost way to generate a defensible data set. Partner with a local university lab, a certified third-party testing facility, or an independent researcher who will put their name on the findings. Document the methodology, publish the raw results, and make the full report available as a PDF behind an email gate. Use the top-line finding in ads, the chart in email, and the full report as the close in objection-handling sequences. Budget **$5,000 to $30,000** depending on study complexity, then treat the research as a multi-year asset that justifies price, builds repeat purchase confidence, and creates a moat against private label.

The broader pattern: as digital ad costs rise and consumer skepticism deepens, brands that can cite third-party proof will win share from those relying on influencer testimonials and marketing language alone. Clinical research is no longer reserved for pharmaceutical companies; it is now table stakes for any physical product making a functional claim in a crowded category.

## The takeaway

Fund a modest clinical study, publish the data, and use it to close buyers who need proof instead of promises.

---

## Publisher

**Hako Shikin LLC** — Virginia Beach, Virginia. Founded 1997. ASI 217876 · DUNS 18-204-6339.
Principal and author: **Jenny Huang Goodman MPA MSc MHSA**.

- Author: https://www.huanggoodman.com/about
- LLM context: https://www.pops4.com/stash/llms.txt
- MCP endpoint, for AI agents: https://mcp.pops4.com/mcp
- Client dashboard: https://dashboard.pops4.com/
- Catalogue: 70,000+ products, 200+ brands